A study of LN-145 for the treatment of cervical cancer.

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
01 Feb 2016 Status changed from planning to not yet recruiting, as reported by Lion Biotechnologies Inc media release.
01 Feb 2016 According to a Lion Biotechnologies Inc media release, the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to conduct this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com